{"id":980,"date":"2026-11-18T10:44:13","date_gmt":"2026-11-18T10:44:13","guid":{"rendered":"https:\/\/theapnachhattisgarh.com\/?p=980"},"modified":"2026-11-18T10:44:13","modified_gmt":"2026-11-18T10:44:13","slug":"indian-drugmakers-take-generic-semaglutide-battle-to-overseas-markets-industry-news","status":"publish","type":"post","link":"https:\/\/theapnachhattisgarh.com\/?p=980","title":{"rendered":"Indian drugmakers take generic semaglutide battle to overseas markets | Industry News"},"content":{"rendered":"<p><br \/>\n<\/p>\n<div id=\"parent_top_div\" style=\"margin:0 0\">\n<p>Indian pharmaceutical companies are taking the generic semaglutide battle overseas, with some already launching the blockbuster diabetes and weight-loss drug in international markets and others lining up regulatory approvals and marketing partnerships.<\/p>\n<p><small class=\"brtag\">\u00a0<\/small><\/p>\n<p>The push comes as the domestic market, which witnessed a rush of generic launches following the expiry of Novo Nordisk\u2019s patent in March, adjusts to growing competition, price erosion and elevated channel inventories.<\/p>\n<p><small class=\"brtag\">\u00a0<\/small><\/p>\n<p>Dr Reddy\u2019s Laboratories, Sun Pharma and Hetero are among the early movers, while Lupin, Biocon and Ajanta Pharma are looking to tap international markets through partnerships.<\/p>\n<p><small class=\"brtag\">\u00a0<\/small><\/p>\n<p>Dr Reddy\u2019s Laboratories, which launched generic semaglutide in Canada earlier this year, received approval from Brazil\u2019s health regulator, ANVISA, earlier this month.<\/p>\n<p><span style=\"display:block;height:1px\">\u00a0<\/span><small class=\"brtag\">\u00a0<\/small><\/p>\n<p>The company has reported approvals in 10 countries. However, its Canadian supplies were disrupted following a recall involving an impurity exceeding specifications and a separate packaging and labelling error.<\/p>\n<p><small class=\"brtag\">\u00a0<\/small><\/p>\n<p>Dr Reddy\u2019s is targeting supplies of 6-7 million semaglutide pens across 10 markets in the second half of FY27, with Canada expected to account for the bulk of the volumes.<\/p>\n<p><small class=\"brtag\">\u00a0<\/small><\/p>\n<p>During the company\u2019s October earnings call, chief executive Erez Israeli said supplies were expected to resume in November, subject to successful product validation.<\/p>\n<p><small class=\"brtag\">\u00a0<\/small><\/p>\n<p>Despite the disruption, the company remains bullish on Canada. During an interaction with journalists in October, its management said the market remained underserved, with insufficient generic competition.<\/p>\n<p><small class=\"brtag\">\u00a0<\/small><\/p>\n<p>Israeli also highlighted opportunities in other markets, including Chile, where Dr Reddy\u2019s has secured approval as the first generic entrant.<\/p>\n<p><small class=\"brtag\">\u00a0<\/small><\/p>\n<p>Sun Pharma has also entered international markets, launching generic semaglutide in South Africa in July, while its local partner has commercially launched the product in Brazil.<\/p>\n<p><small class=\"brtag\">\u00a0<\/small><\/p>\n<p>During the company\u2019s October earnings call, managing director Kirti Ganorkar confirmed that semaglutide had been commercialised in both markets.<\/p>\n<p><small class=\"brtag\">\u00a0<\/small><\/p>\n<p>Asked whether these countries were witnessing price erosion similar to India, Ganorkar said pricing decisions in Brazil were being taken by its local partner and declined to comment on the extent of price reductions.<\/p>\n<p><small class=\"brtag\">\u00a0<\/small><\/p>\n<p>Hetero, meanwhile, has begun exporting the drug to markets across Africa, Asia and the Middle East under three brands, with plans to eventually expand into more than 75 countries.<\/p>\n<p><small class=\"brtag\">\u00a0<\/small><\/p>\n<p>Its manufacturing partner, Gufic Biosciences, said during an August earnings call that the two companies had filed for regulatory approvals in more than 22 countries.<\/p>\n<p><small class=\"brtag\">\u00a0<\/small><\/p>\n<p>During its November earnings call, Gufic indicated that revenue from these international registrations was expected to begin in the first or second quarter of the next financial year, subject to regulatory approvals.<\/p>\n<p><small class=\"brtag\">\u00a0<\/small><\/p>\n<p>The opportunity is also attracting other Indian pharmaceutical companies.<\/p>\n<p><small class=\"brtag\">\u00a0<\/small><\/p>\n<p>Lupin has signed an agreement with Spain\u2019s Galenicum to commercialise semaglutide across 23 countries.<\/p>\n<p><small class=\"brtag\">\u00a0<\/small><\/p>\n<p>Biocon has partnered with Ajanta Pharma to supply the drug for marketing in 26 countries across Africa, the Middle East and Central Asia.<\/p>\n<p><small class=\"brtag\">\u00a0<\/small><\/p>\n<p>Ajanta, however, expects commercial sales to begin only in FY28 as it works through regulatory approvals in these markets.<\/p>\n<p><small class=\"brtag\">\u00a0<\/small><\/p>\n<p>Overseas markets offer considerable opportunities for Indian generic manufacturers, although the competitive dynamics vary across countries.<\/p>\n<p><small class=\"brtag\">\u00a0<\/small><\/p>\n<p>Canada, where Dr Reddy\u2019s has already launched the drug, uses nearly 12 million semaglutide injection pens annually, while its broader glucagon-like peptide-1 (GLP-1) market is estimated at $2.6 billion, according to data cited by Sandoz.<\/p>\n<p><small class=\"brtag\">\u00a0<\/small><\/p>\n<p>Brazil\u2019s semaglutide market for diabetes is worth around $245 million, according to IQVIA data cited by Dr Reddy\u2019s.<\/p>\n<p><small class=\"brtag\">\u00a0<\/small><\/p>\n<p>However, generic competition is playing out differently in the two markets.<\/p>\n<p><small class=\"brtag\">\u00a0<\/small><\/p>\n<p>In Canada, Novo Nordisk has managed to retain a substantial share of its business despite the expiry of patent protection in January, partly because of delays in generic launches.<\/p>\n<p><small class=\"brtag\">\u00a0<\/small><\/p>\n<p>Brazil, on the other hand, is already witnessing a shift towards lower-priced alternatives. Novo Nordisk has acknowledged losing market share to cheaper competitors following the March patent expiry.<\/p>\n<p><small class=\"brtag\">\u00a0<\/small><\/p>\n<p>The Danish drugmaker said pricing pressure in Brazil contributed to a 3 per cent decline in its emerging-market sales in the September quarter.<\/p>\n<p><small class=\"brtag\">\u00a0<\/small><\/p>\n<p>Competition is also increasing, with Sandoz launching its semaglutide injection in Brazil earlier this month.<\/p>\n<p><small class=\"brtag\">\u00a0<\/small><\/p>\n<p>In South Africa, where Sun Pharma has launched its product, the GLP-1 market is approaching $182 million, according to figures from Aspen Pharmacare.<\/p>\n<p><small class=\"brtag\">\u00a0<\/small><\/p>\n<p>However, much of this market is currently driven by tirzepatide, another widely used medicine for diabetes and weight management.<\/p>\n<p><small class=\"brtag\">\u00a0<\/small><\/p>\n<p>The country is also attracting more generic semaglutide manufacturers.<\/p>\n<p><small class=\"brtag\">\u00a0<\/small><\/p>\n<p>South Africa\u2019s medicines regulator was reviewing 12 generic applications in July, while Aspen secured approval for its semaglutide injection earlier this month.<\/p>\n<p><small class=\"brtag\">\u00a0<\/small><\/p>\n<p>The entry of additional manufacturers could widen access to lower-priced versions of the drug, although competition is expected to intensify as more products enter the market.<\/p>\n<p><small class=\"brtag\">\u00a0<\/small><\/p>\n<p>Back home, the market is settling down after the initial rush that followed the expiry of Novo Nordisk\u2019s semaglutide patent in March.<\/p>\n<p><small class=\"brtag\">\u00a0<\/small><\/p>\n<p>According to Pharmarack\u2019s PharmaTrac data, monthly semaglutide volumes jumped from 1.14 lakh units in February to 4.34 lakh units in September.<\/p>\n<p><small class=\"brtag\">\u00a0<\/small><\/p>\n<p>Sales value, however, increased at a slower pace, from Rs 48 crore to Rs 113 crore, as cheaper generic versions gained ground.<\/p>\n<p><small class=\"brtag\">\u00a0<\/small><\/p>\n<p>Generic brands accounted for around 74 per cent of total semaglutide volumes in September.<\/p>\n<p><small class=\"brtag\">\u00a0<\/small><\/p>\n<p>However, the pace of growth has moderated since the first wave of launches. Monthly volumes surged 88 per cent in April, before growth eased to 12 per cent in May and 4 per cent in June.<\/p>\n<p><small class=\"brtag\">\u00a0<\/small><\/p>\n<p>After remaining largely flat in August, volumes increased 7 per cent in September.<\/p>\n<p><small class=\"brtag\">\u00a0<\/small><\/p>\n<p>The rush of launches also resulted in substantial stocking across the distribution chain.<\/p>\n<p><small class=\"brtag\">\u00a0<\/small><\/p>\n<p>PharmaTrac data showed that inventory increased from 16 days in February to a peak of 26 days in May, before easing to 23 days in August. Some individual brands recorded considerably higher inventory levels, reflecting the rush to stock products ahead of actual demand.<\/p>\n<p><small class=\"brtag\">\u00a0<\/small><\/p>\n<p>Nirali Shah, research analyst at Ashika Investment Managers, had earlier told Business Standard that India\u2019s semaglutide market was moving from a \u201cbuzz phase\u201d to a \u201cprescription habit phase\u201d, as the initial excitement surrounding generic launches gave way to the need for sustained patient demand.<\/p>\n<p><small class=\"brtag\">\u00a0<\/small><\/p>\n<p>While domestic sales volumes continue to rise, the sharp increase in the number of generic brands has intensified competition.<\/p>\n<p><small class=\"brtag\">\u00a0<\/small><\/p>\n<p>For Indian pharmaceutical companies, overseas markets offer another avenue for growth, particularly in countries where semaglutide demand is already established and lower-priced alternatives could attract more patients.<\/p>\n<p><small class=\"brtag\">\u00a0<\/small><\/p>\n<p>However, the international expansion is not necessarily a response to inventory accumulation in India. Several companies had begun working on overseas regulatory approvals and commercial partnerships well before the domestic patent expired.<\/p>\n<p><small class=\"brtag\">\u00a0<\/small><\/p>\n<blockquote class=\"blockquoteBG styleQ1\" style=\"background-color:#FFF5EB;padding:8px;overflow:hidden\">\n<p><strong>Indian pharma\u2019s overseas semaglutide push<\/strong><\/p>\n<p><small class=\"brtag\">\u00a0<\/small><\/p>\n<ul>\n<li>Dr Reddy\u2019s: Launched in Canada; secured Brazilian approval in November. Reported approvals in 10 countries and targets 6\u20137 million pens across 10 markets in H2 FY27.<\/li>\n<li>Sun Pharma: Commercialised generic semaglutide in South Africa and, through its partner, Brazil.<\/li>\n<li>Hetero: Begun exports to Africa, Asia and the Middle East; plans expansion to over 75 countries. Manufacturing partner Gufic has filed for approvals in more than 22 countries.<\/li>\n<li>Lupin: Partnership with Galenicum covering 23 countries.<\/li>\n<li>Biocon\u2013Ajanta: Partnership covering 26 countries; Ajanta expects sales from FY28.<\/li>\n<li>Overseas market opportunity<\/li>\n<li>Canada: GLP-1 market estimated at $2.6 billion; nearly 12 million semaglutide injection pens used annually. Novo Nordisk has retained much of its business despite generic entry.<\/li>\n<li>Brazil: Diabetes semaglutide market worth around $245 million. Cheaper alternatives are gaining share, putting pressure on Novo Nordisk.<\/li>\n<li>South Africa: GLP-1 market approaching $182 million, with tirzepatide accounting for more than half. Generic competition is growing.<\/li>\n<\/ul>\n<\/blockquote>\n<p><small class=\"brtag\">\u00a0<\/small><\/p>\n<\/div>\n\n","protected":false},"excerpt":{"rendered":"<p>Indian pharmaceutical companies are taking the generic semaglutide battle overseas, with some already launching the blockbuster diabetes and<\/p>\n","protected":false},"author":1,"featured_media":981,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_hide_featured_image":false,"_jetpack_featured_image_duplicate_dismissed":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[21],"tags":[],"class_list":["post-980","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-india"],"aioseo_notices":[],"aioseo_head":"\n\t\t<!-- All in One SEO 5.0.5.1 - aioseo.com -->\n\t<meta name=\"description\" content=\"Indian pharmaceutical companies are taking the generic semaglutide battle overseas, with some already launching the blockbuster diabetes and weight-loss drug in international markets and others lining up regulatory approvals and marketing partnerships. The push comes as the domestic market, which witnessed a rush of generic launches following the expiry of Novo Nordisk\u2019s patent in\" \/>\n\t<meta name=\"robots\" content=\"max-image-preview:large\" \/>\n\t<meta name=\"author\" content=\"The Apna Chhattisgarh\"\/>\n\t<link rel=\"canonical\" href=\"https:\/\/theapnachhattisgarh.com\/?p=980\" \/>\n\t\t<meta name=\"generator\" content=\"All in One SEO (AIOSEO) 5.0.5.1\" \/>\n\t\t<meta property=\"og:locale\" content=\"en_US\" \/>\n\t\t<meta property=\"og:site_name\" content=\"The Apna Chhattisgarh -\" \/>\n\t\t<meta property=\"og:type\" content=\"article\" \/>\n\t\t<meta property=\"og:title\" content=\"Indian drugmakers take generic semaglutide battle to overseas markets | Industry News - The Apna Chhattisgarh\" \/>\n\t\t<meta property=\"og:description\" content=\"Indian pharmaceutical companies are taking the generic semaglutide battle overseas, with some already launching the blockbuster diabetes and weight-loss drug in international markets and others lining up regulatory approvals and marketing partnerships. The push comes as the domestic market, which witnessed a rush of generic launches following the expiry of Novo Nordisk\u2019s patent in\" \/>\n\t\t<meta property=\"og:url\" content=\"https:\/\/theapnachhattisgarh.com\/?p=980\" \/>\n\t\t<meta property=\"og:image\" content=\"https:\/\/theapnachhattisgarh.com\/wp-content\/uploads\/2026\/11\/1794998218_1788973509-2677.jpg\" \/>\n\t\t<meta property=\"og:image:secure_url\" content=\"https:\/\/theapnachhattisgarh.com\/wp-content\/uploads\/2026\/11\/1794998218_1788973509-2677.jpg\" \/>\n\t\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t\t<meta property=\"og:image:height\" content=\"628\" \/>\n\t\t<meta property=\"article:published_time\" content=\"2026-11-18T10:44:13+00:00\" \/>\n\t\t<meta property=\"article:modified_time\" content=\"2026-11-18T10:44:13+00:00\" \/>\n\t\t<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n\t\t<meta name=\"twitter:title\" content=\"Indian drugmakers take generic semaglutide battle to overseas markets | Industry News - The Apna Chhattisgarh\" \/>\n\t\t<meta name=\"twitter:description\" content=\"Indian pharmaceutical companies are taking the generic semaglutide battle overseas, with some already launching the blockbuster diabetes and weight-loss drug in international markets and others lining up regulatory approvals and marketing partnerships. The push comes as the domestic market, which witnessed a rush of generic launches following the expiry of Novo Nordisk\u2019s patent in\" \/>\n\t\t<meta name=\"twitter:image\" content=\"https:\/\/theapnachhattisgarh.com\/wp-content\/uploads\/2026\/11\/1794998218_1788973509-2677.jpg\" \/>\n\t\t<script type=\"application\/ld+json\" class=\"aioseo-schema\">\n\t\t\t{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"BlogPosting\",\"@id\":\"https:\\\/\\\/theapnachhattisgarh.com\\\/?p=980#blogposting\",\"name\":\"Indian drugmakers take generic semaglutide battle to overseas markets | Industry News - The Apna Chhattisgarh\",\"headline\":\"Indian drugmakers take generic semaglutide battle to overseas markets | Industry News\",\"author\":{\"@id\":\"https:\\\/\\\/theapnachhattisgarh.com\\\/?author=1#author\"},\"publisher\":{\"@id\":\"https:\\\/\\\/theapnachhattisgarh.com\\\/#organization\"},\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/theapnachhattisgarh.com\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/1794998218_1788973509-2677.jpg\",\"width\":1200,\"height\":628},\"datePublished\":\"2026-11-18T10:44:13+00:00\",\"dateModified\":\"2026-11-18T10:44:13+00:00\",\"inLanguage\":\"en-US\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/theapnachhattisgarh.com\\\/?p=980#webpage\"},\"isPartOf\":{\"@id\":\"https:\\\/\\\/theapnachhattisgarh.com\\\/?p=980#webpage\"},\"articleSection\":\"India\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/theapnachhattisgarh.com\\\/?p=980#breadcrumblist\",\"itemListElement\":[{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/theapnachhattisgarh.com\\\/#listItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/theapnachhattisgarh.com\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/theapnachhattisgarh.com\\\/?cat=21#listItem\",\"name\":\"India\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/theapnachhattisgarh.com\\\/?cat=21#listItem\",\"position\":2,\"name\":\"India\",\"item\":\"https:\\\/\\\/theapnachhattisgarh.com\\\/?cat=21\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/theapnachhattisgarh.com\\\/?p=980#listItem\",\"name\":\"Indian drugmakers take generic semaglutide battle to overseas markets | Industry News\"},\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/theapnachhattisgarh.com\\\/#listItem\",\"name\":\"Home\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/theapnachhattisgarh.com\\\/?p=980#listItem\",\"position\":3,\"name\":\"Indian drugmakers take generic semaglutide battle to overseas markets | Industry News\",\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/theapnachhattisgarh.com\\\/?cat=21#listItem\",\"name\":\"India\"}}]},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/theapnachhattisgarh.com\\\/#organization\",\"name\":\"The Apna Chhattisgarh\",\"url\":\"https:\\\/\\\/theapnachhattisgarh.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/theapnachhattisgarh.com\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/cropped-WhatsApp-Image-2026-10-24-at-10.47.40-PM.jpeg\",\"@id\":\"https:\\\/\\\/theapnachhattisgarh.com\\\/?p=980\\\/#organizationLogo\",\"width\":1597,\"height\":362},\"image\":{\"@id\":\"https:\\\/\\\/theapnachhattisgarh.com\\\/?p=980\\\/#organizationLogo\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/theapnachhattisgarh.com\\\/?author=1#author\",\"url\":\"https:\\\/\\\/theapnachhattisgarh.com\\\/?author=1\",\"name\":\"The Apna Chhattisgarh\",\"image\":{\"@type\":\"ImageObject\",\"@id\":\"https:\\\/\\\/theapnachhattisgarh.com\\\/?p=980#authorImage\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/af79d0a817c8720a95b0601916cbb419fbcc63fe5df7fc5a696773013f741e58?s=96&d=mm&r=g\",\"width\":96,\"height\":96,\"caption\":\"The Apna Chhattisgarh\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/theapnachhattisgarh.com\\\/?p=980#webpage\",\"url\":\"https:\\\/\\\/theapnachhattisgarh.com\\\/?p=980\",\"name\":\"Indian drugmakers take generic semaglutide battle to overseas markets | Industry News - The Apna Chhattisgarh\",\"description\":\"Indian pharmaceutical companies are taking the generic semaglutide battle overseas, with some already launching the blockbuster diabetes and weight-loss drug in international markets and others lining up regulatory approvals and marketing partnerships. The push comes as the domestic market, which witnessed a rush of generic launches following the expiry of Novo Nordisk\\u2019s patent in\",\"inLanguage\":\"en-US\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/theapnachhattisgarh.com\\\/#website\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/theapnachhattisgarh.com\\\/?p=980#breadcrumblist\"},\"author\":{\"@id\":\"https:\\\/\\\/theapnachhattisgarh.com\\\/?author=1#author\"},\"creator\":{\"@id\":\"https:\\\/\\\/theapnachhattisgarh.com\\\/?author=1#author\"},\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/theapnachhattisgarh.com\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/1794998218_1788973509-2677.jpg\",\"@id\":\"https:\\\/\\\/theapnachhattisgarh.com\\\/?p=980\\\/#mainImage\",\"width\":1200,\"height\":628},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/theapnachhattisgarh.com\\\/?p=980#mainImage\"},\"datePublished\":\"2026-11-18T10:44:13+00:00\",\"dateModified\":\"2026-11-18T10:44:13+00:00\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/theapnachhattisgarh.com\\\/#website\",\"url\":\"https:\\\/\\\/theapnachhattisgarh.com\\\/\",\"name\":\"The Apna Chhattisgarh\",\"inLanguage\":\"en-US\",\"publisher\":{\"@id\":\"https:\\\/\\\/theapnachhattisgarh.com\\\/#organization\"}}]}\n\t\t<\/script>\n\t\t<!-- All in One SEO -->\n\n","aioseo_head_json":{"title":"Indian drugmakers take generic semaglutide battle to overseas markets | Industry News - The Apna Chhattisgarh","description":"Indian pharmaceutical companies are taking the generic semaglutide battle overseas, with some already launching the blockbuster diabetes and weight-loss drug in international markets and others lining up regulatory approvals and marketing partnerships. The push comes as the domestic market, which witnessed a rush of generic launches following the expiry of Novo Nordisk\u2019s patent in","canonical_url":"https:\/\/theapnachhattisgarh.com\/?p=980","robots":"max-image-preview:large","keywords":"","webmasterTools":{"miscellaneous":""},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"BlogPosting","@id":"https:\/\/theapnachhattisgarh.com\/?p=980#blogposting","name":"Indian drugmakers take generic semaglutide battle to overseas markets | Industry News - The Apna Chhattisgarh","headline":"Indian drugmakers take generic semaglutide battle to overseas markets | Industry News","author":{"@id":"https:\/\/theapnachhattisgarh.com\/?author=1#author"},"publisher":{"@id":"https:\/\/theapnachhattisgarh.com\/#organization"},"image":{"@type":"ImageObject","url":"https:\/\/theapnachhattisgarh.com\/wp-content\/uploads\/2026\/11\/1794998218_1788973509-2677.jpg","width":1200,"height":628},"datePublished":"2026-11-18T10:44:13+00:00","dateModified":"2026-11-18T10:44:13+00:00","inLanguage":"en-US","mainEntityOfPage":{"@id":"https:\/\/theapnachhattisgarh.com\/?p=980#webpage"},"isPartOf":{"@id":"https:\/\/theapnachhattisgarh.com\/?p=980#webpage"},"articleSection":"India"},{"@type":"BreadcrumbList","@id":"https:\/\/theapnachhattisgarh.com\/?p=980#breadcrumblist","itemListElement":[{"@type":"ListItem","@id":"https:\/\/theapnachhattisgarh.com\/#listItem","position":1,"name":"Home","item":"https:\/\/theapnachhattisgarh.com\/","nextItem":{"@type":"ListItem","@id":"https:\/\/theapnachhattisgarh.com\/?cat=21#listItem","name":"India"}},{"@type":"ListItem","@id":"https:\/\/theapnachhattisgarh.com\/?cat=21#listItem","position":2,"name":"India","item":"https:\/\/theapnachhattisgarh.com\/?cat=21","nextItem":{"@type":"ListItem","@id":"https:\/\/theapnachhattisgarh.com\/?p=980#listItem","name":"Indian drugmakers take generic semaglutide battle to overseas markets | Industry News"},"previousItem":{"@type":"ListItem","@id":"https:\/\/theapnachhattisgarh.com\/#listItem","name":"Home"}},{"@type":"ListItem","@id":"https:\/\/theapnachhattisgarh.com\/?p=980#listItem","position":3,"name":"Indian drugmakers take generic semaglutide battle to overseas markets | Industry News","previousItem":{"@type":"ListItem","@id":"https:\/\/theapnachhattisgarh.com\/?cat=21#listItem","name":"India"}}]},{"@type":"Organization","@id":"https:\/\/theapnachhattisgarh.com\/#organization","name":"The Apna Chhattisgarh","url":"https:\/\/theapnachhattisgarh.com\/","logo":{"@type":"ImageObject","url":"https:\/\/theapnachhattisgarh.com\/wp-content\/uploads\/2026\/10\/cropped-WhatsApp-Image-2026-10-24-at-10.47.40-PM.jpeg","@id":"https:\/\/theapnachhattisgarh.com\/?p=980\/#organizationLogo","width":1597,"height":362},"image":{"@id":"https:\/\/theapnachhattisgarh.com\/?p=980\/#organizationLogo"}},{"@type":"Person","@id":"https:\/\/theapnachhattisgarh.com\/?author=1#author","url":"https:\/\/theapnachhattisgarh.com\/?author=1","name":"The Apna Chhattisgarh","image":{"@type":"ImageObject","@id":"https:\/\/theapnachhattisgarh.com\/?p=980#authorImage","url":"https:\/\/secure.gravatar.com\/avatar\/af79d0a817c8720a95b0601916cbb419fbcc63fe5df7fc5a696773013f741e58?s=96&d=mm&r=g","width":96,"height":96,"caption":"The Apna Chhattisgarh"}},{"@type":"WebPage","@id":"https:\/\/theapnachhattisgarh.com\/?p=980#webpage","url":"https:\/\/theapnachhattisgarh.com\/?p=980","name":"Indian drugmakers take generic semaglutide battle to overseas markets | Industry News - The Apna Chhattisgarh","description":"Indian pharmaceutical companies are taking the generic semaglutide battle overseas, with some already launching the blockbuster diabetes and weight-loss drug in international markets and others lining up regulatory approvals and marketing partnerships. The push comes as the domestic market, which witnessed a rush of generic launches following the expiry of Novo Nordisk\u2019s patent in","inLanguage":"en-US","isPartOf":{"@id":"https:\/\/theapnachhattisgarh.com\/#website"},"breadcrumb":{"@id":"https:\/\/theapnachhattisgarh.com\/?p=980#breadcrumblist"},"author":{"@id":"https:\/\/theapnachhattisgarh.com\/?author=1#author"},"creator":{"@id":"https:\/\/theapnachhattisgarh.com\/?author=1#author"},"image":{"@type":"ImageObject","url":"https:\/\/theapnachhattisgarh.com\/wp-content\/uploads\/2026\/11\/1794998218_1788973509-2677.jpg","@id":"https:\/\/theapnachhattisgarh.com\/?p=980\/#mainImage","width":1200,"height":628},"primaryImageOfPage":{"@id":"https:\/\/theapnachhattisgarh.com\/?p=980#mainImage"},"datePublished":"2026-11-18T10:44:13+00:00","dateModified":"2026-11-18T10:44:13+00:00"},{"@type":"WebSite","@id":"https:\/\/theapnachhattisgarh.com\/#website","url":"https:\/\/theapnachhattisgarh.com\/","name":"The Apna Chhattisgarh","inLanguage":"en-US","publisher":{"@id":"https:\/\/theapnachhattisgarh.com\/#organization"}}]},"og:locale":"en_US","og:site_name":"The Apna Chhattisgarh -","og:type":"article","og:title":"Indian drugmakers take generic semaglutide battle to overseas markets | Industry News - The Apna Chhattisgarh","og:description":"Indian pharmaceutical companies are taking the generic semaglutide battle overseas, with some already launching the blockbuster diabetes and weight-loss drug in international markets and others lining up regulatory approvals and marketing partnerships. The push comes as the domestic market, which witnessed a rush of generic launches following the expiry of Novo Nordisk\u2019s patent in","og:url":"https:\/\/theapnachhattisgarh.com\/?p=980","og:image":"https:\/\/theapnachhattisgarh.com\/wp-content\/uploads\/2026\/11\/1794998218_1788973509-2677.jpg","og:image:secure_url":"https:\/\/theapnachhattisgarh.com\/wp-content\/uploads\/2026\/11\/1794998218_1788973509-2677.jpg","og:image:width":1200,"og:image:height":628,"article:published_time":"2026-11-18T10:44:13+00:00","article:modified_time":"2026-11-18T10:44:13+00:00","twitter:card":"summary_large_image","twitter:title":"Indian drugmakers take generic semaglutide battle to overseas markets | Industry News - The Apna Chhattisgarh","twitter:description":"Indian pharmaceutical companies are taking the generic semaglutide battle overseas, with some already launching the blockbuster diabetes and weight-loss drug in international markets and others lining up regulatory approvals and marketing partnerships. The push comes as the domestic market, which witnessed a rush of generic launches following the expiry of Novo Nordisk\u2019s patent in","twitter:image":"https:\/\/theapnachhattisgarh.com\/wp-content\/uploads\/2026\/11\/1794998218_1788973509-2677.jpg"},"aioseo_meta_data":[],"aioseo_breadcrumb":"<div class=\"aioseo-breadcrumbs\"><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"https:\/\/theapnachhattisgarh.com\/\" title=\"Home\">Home<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">\u00bb<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"https:\/\/theapnachhattisgarh.com\/?cat=21\" title=\"India\">India<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">\u00bb<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\tIndian drugmakers take generic semaglutide battle to overseas markets | Industry News\n\t\t<\/span><\/div>","aioseo_breadcrumb_json":[{"label":"Home","link":"https:\/\/theapnachhattisgarh.com\/"},{"label":"India","link":"https:\/\/theapnachhattisgarh.com\/?cat=21"},{"label":"Indian drugmakers take generic semaglutide battle to overseas markets | Industry News","link":"https:\/\/theapnachhattisgarh.com\/?p=980"}],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/theapnachhattisgarh.com\/wp-content\/uploads\/2026\/11\/1794998218_1788973509-2677.jpg","_links":{"self":[{"href":"https:\/\/theapnachhattisgarh.com\/index.php?rest_route=\/wp\/v2\/posts\/980","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/theapnachhattisgarh.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/theapnachhattisgarh.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/theapnachhattisgarh.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/theapnachhattisgarh.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=980"}],"version-history":[{"count":0,"href":"https:\/\/theapnachhattisgarh.com\/index.php?rest_route=\/wp\/v2\/posts\/980\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/theapnachhattisgarh.com\/index.php?rest_route=\/wp\/v2\/media\/981"}],"wp:attachment":[{"href":"https:\/\/theapnachhattisgarh.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=980"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/theapnachhattisgarh.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=980"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/theapnachhattisgarh.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=980"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}